---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-210794"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:17:51.475935+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CalciMedica updates biz description with CARPO trial expansion, AKI plans, recasted financials

## Summary
- CARPO Phase 2b in AP+SIRS expanded to India; topline results expected first half 2024.
- CRSPA Phase 1/2 in pediatric AIPT completed first cohort; data publication expected Q4 2023.
- AKI plan: IND submission H2 2023; Phase 2 trial H1 2024 subject to additional funding.
- CARDEA trial showed 56% relative mortality reduction at 30 days (p=0.0165) in severe COVID-19 pneumonia.
- Audited recasted financial statements of Private CalciMedica as of Dec 31, 2022 and 2021 filed.

## SEC filing metadata
- accession: 0001193125-23-210794
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312523210794/0001193125-23-210794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312523210794/d441914d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-210794
- JSON: https://secwatch.observer/filing/0001193125-23-210794.json
- Plain text: https://secwatch.observer/filing/0001193125-23-210794.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.